



Immunotherapy: Hacking How the Body Fights Disease

Immunotherapy researchers are applying new insights into how the immune system works to unleash its power on cancer and fight autoimmune diseases like diabetes, MS, and rheumatoid arthritis. Private investors, VCs, and pharmaceutical companies are investing hundreds of millions of dollars into groundbreaking immunotherapies, and clinicians are scrambling to identify and test the most promising treatments.

In spite of the huge expense, time-consuming research, rigorous clinical testing, and FDA approval requirements, startups, non-profit organizations, and established companies alike are racing to bring the next immunotherapy to market. Radically different approaches will stand alone, be combined, or fail in crunch time. According to market research firm MarketsandMarkets, the global immunotherapy market is expected to grow at a CAGR of 13.5%, reaching \$201B by 2021, promising huge returns.

Biopharma companies like Merck, Novartis, Roche, and BMS are all-in.

- With high barriers to entry, are startups able to compete?
- What strategies are companies taking to be the first to market?
- Will cancer, allergies, and autoimmune disease someday be a thing of the past?

Join us on March 21, 2017, to find out.

Moderator

Tito Serafini
CEO & Chief Scientific Officer, Atreca

Panelists

Jonathan MacQuitty
CEO, Forty Seven Inc.

Karin Jooss
Executive VP of Research & Chief
Scientific Officer, Gritstone Oncology

Edgar Engleman
Professor of Pathology and of Medicine,
Stanford University

Tuesday, March 21, 2017

6:00 pm – 8:30 pm

6:00 pm:
Reception and demos
7:00 pm:
Panel discussion (with Q&A)

SRI International Conference Center

333 Ravenswood Drive
Menlo Park, CA 94025

Register at the URL below.